A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

NCT05931380 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of a once-daily oral medication called orforglipron in Japanese adults who have obesity.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 238 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-07 · est. completion 2025-06

Where 16 sites · Japan

What this study is testing ClinicalTrials.gov NCT05931380 ↗

Description as written by the study sponsor.

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

Treatments tested

Orforglipron Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Mean Percent Change in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05931380 ↗